Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Egg cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Egg cell. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-001534-13 Sponsor Protocol Number: V58P12 Start Date*: 2007-11-08
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cel...
    Medical condition: Healthy pediatric population from 3-17 years
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017141-58 Sponsor Protocol Number: V111_06TP_OPERA Start Date*: 2009-11-19
    Sponsor Name:OPERA SRL
    Full Title: An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovale...
    Medical condition: Prophylaxis of A/H1N1sw influenza
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022001 Influenza (epidemic) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002871-15 Sponsor Protocol Number: V58P13 Start Date*: 2007-09-14
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine i...
    Medical condition: Influenza disease.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-004164-23 Sponsor Protocol Number: 710501 Start Date*: 2006-01-09
    Sponsor Name:Baxter AG
    Full Title: Single-blind, Randomized, Controlled Phase I/II Study to Compare the Safety and Immunogenicity of an Inactivated Influenza Vaccine (Whole Virion, Vero cell derived) with a Licensed Egg derived Infl...
    Medical condition: Influenza Vaccination in healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005191-41 Sponsor Protocol Number: 720601 Start Date*: 2007-01-25
    Sponsor Name:Baxter Healthcare Corporation, Baxter BioScience
    Full Title: Single blind, randomized, active controlled Phase 1/2 study to compare the safety and immunogenicity of a Split Virus, Vero cell-derived, seasonal influenza vaccine (VCIV) with a licensed egg-deriv...
    Medical condition: Influenza Vaccination in healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013639-39 Sponsor Protocol Number: V110_03 Start Date*: 2009-07-29
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-Derived, Inactivated Novel Swine ...
    Medical condition: Pandemic influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002785-13 Sponsor Protocol Number: V130_10 Start Date*: 2020-12-04
    Sponsor Name:Seqirus Inc.
    Full Title: A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United State...
    Medical condition: Prophylaxis of Influenza Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001223-13 Sponsor Protocol Number: V58_31 Start Date*: 2014-12-03
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Ch...
    Medical condition: Prophylaxis: Influenza
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002872-32 Sponsor Protocol Number: V58P14 Start Date*: 2007-11-01
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture (Optaflu®) or in Embryona...
    Medical condition: no medical condition: healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001374-34 Sponsor Protocol Number: 231 Start Date*: 2005-01-03
    Sponsor Name:Baxter Vaccine AG
    Full Title: SINGLE-BLIND RANDOMIZED CONTROLLED PHASE II/III STUDY TO INVESTIGATE THE IMMUNOGENICITY AND SAFETY AFTER A SINGLE VACCINATION WITH ONE OF THREE DIFFERENT LOTS OF AN INACTIVATED INFLUENZA VACCINE (W...
    Medical condition: Influenza Vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013640-37 Sponsor Protocol Number: V110_04 Start Date*: 2009-07-31
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-derived, Inactivated Novel Swine O...
    Medical condition: Pandemic influenza
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002257-47 Sponsor Protocol Number: V58P9 Start Date*: 2005-08-24
    Sponsor Name:Chiron S.r.l.
    Full Title: A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of Trivalent Subunit Influen...
    Medical condition: Influenza
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000994-22 Sponsor Protocol Number: GADOTATOC-EUS Start Date*: 2011-11-09
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Accuracy and clinical impact of 68-Ga-labeled octreotide analogues PET in diagnosis and staging of duodeno-pancreatic neuroendocrine tumours; proposal of a multicenter, prospective clinical trial
    Medical condition: Patients suspected to be affected by neuroendocrine duodeno-pancreatic neoplasm.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014713 Endocrine neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002329-39 Sponsor Protocol Number: RE06 Start Date*: 2018-01-08
    Sponsor Name:University College London
    Full Title: Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with r...
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003176-16 Sponsor Protocol Number: ADP-0055-003/GOG-3084 Start Date*: 2023-07-03
    Sponsor Name:Adaptimmune LLC
    Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)
    Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005173-20 Sponsor Protocol Number: MEDI4736-DLBCL-001 Start Date*: 2016-12-21
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or...
    Medical condition: Previously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DK (Prematurely Ended) EE (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004081-18 Sponsor Protocol Number: JCAR017-FOL-001 Start Date*: 2020-08-04
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (...
    Medical condition: Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10016895 Follicle centre lymphomas diffuse predominantly small cell HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029460 Nodal marginal zone B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001677-31 Sponsor Protocol Number: AMB-001 Start Date*: 2022-10-28
    Sponsor Name:Aarhus University Hospital
    Full Title: Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in peop...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003801-32 Sponsor Protocol Number: MEDI4736-MM-005 Start Date*: 2017-05-29
    Sponsor Name:Celgene International II Sàrl
    Full Title: Multicenter, Single-arm, Phase 2 Study to Determine the Efficacy for the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RR...
    Medical condition: Relapsed and Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000054086 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) ES (Completed) GR (Completed) NL (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001246-34 Sponsor Protocol Number: JCAR017-BCM-004 Start Date*: 2021-11-15
    Sponsor Name:Celgene Corporation
    Full Title: A phase 1 / 2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL (TRANSCEND PEDALL)
    Medical condition: Relapsed or refractory (r/r) CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL).
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10029593 Non-Hodgkin's lymphoma NOS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) BE (Completed) NL (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 07:03:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA